Retrospective Study
Copyright ©The Author(s) 2025.
World J Clin Cases. Sep 6, 2025; 13(25): 106335
Published online Sep 6, 2025. doi: 10.12998/wjcc.v13.i25.106335
Table 2 Frequency of different symptoms, signs, and laboratory findings of the cohort, n (%)
Clinical variable
Frequency, n = 62
No. of patients from Himalayan region, n = 20
No. of patients from Sub-Himalayan region, n = 42
P value
Fever (> 39 °C)61 (98.39)20 (100.00)41 (97.62)1
Headache20 (32.26)7 (35.00)13 (30.95)0.977565281
Conjunctival suffusion9 (14.52)4 (20.00)5 (11.90)0.452540931
Neck rigidity4 (6.45)0 (0.00)4 (9.52)0.295162635
Myalgia26 (41.94)9 (45.00)17 (40.48)0.950434811
Jaundice13 (20.97)6 (30.00)7 (16.67)0.383257647
Dyspnea15 (24.19)7 (35.00)8 (19.05)0.291929299
Increased liver enzyme (> 3 × upper limit)39 (62.90)14 (70.00)25 (59.52)0.60511935
Thrombocytopenia45 (72.58)14 (70.00)31 (73.81)0.992162843
Edema7 (11.29)4 (20.00)3 (7.14)0.198564612
Abdominal pain27 (43.55)11 (55.00)16 (38.10)0.326599126
AKI25 (40.32)10 (50.00)15 (35.71)0.426604756
Hemodialysis Required14 (22.58)8 (40.00)6 (14.29)0.052520105
Altered sensorium16 (25.81)6 (30.00)10 (23.81)0.833434549
ARDS12 (19.35)7 (35.00)5 (11.90)0.070626099
CKD4 (6.45)2 (10.00)2 (4.76)0.588416137
DIC8 (12.90)2 (10.00)5 (11.90)1
MODS41 (66.13)13 (65.00)28 (66.67)1
HDU or ICU requirement37 (59.67)13 (65.00)24 (57.14)0.754549351